Understanding how to improve responses to cancer immunotherapy
Determinants of response to cancer immunotherapy
This study is looking at what helps or hinders cancer patients from responding well to immunotherapy treatments, especially those that use immune checkpoint inhibitors, to find better ways to personalize these therapies and improve outcomes for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11100664 on NIH RePORTER |
What this research studies
This research investigates the factors that influence how well patients respond to cancer immunotherapy, particularly focusing on immune checkpoint inhibitors. By utilizing advanced techniques like single-cell RNA sequencing, the study aims to identify specific immune cells and pathways that either promote or hinder effective treatment responses. The researchers will explore combination therapies that target immunosuppressive cells to enhance the effectiveness of existing treatments. This work is crucial for developing personalized immunotherapy strategies that could lead to better outcomes for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with advanced cancer who are undergoing immunotherapy treatments.
Not a fit: Patients with early-stage cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments that provide longer-lasting responses for cancer patients.
How similar studies have performed: Previous research has shown promise in enhancing immunotherapy responses through combination therapies, indicating that this approach could yield significant advancements.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Fong, Lawrence — Fred Hutchinson Cancer Center
- Study coordinator: Fong, Lawrence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.